MEDICURE TO PRESENT FINANCIAL RESULTS ON NOVEMBER 26, 2024 CALL at 8:30 AM ET FOR QUARTER ENDED SEPTEMBER 30, 2024 AND ANNOUNCES RESIGNATION OF BOARD MEMBER
November 18, 2024
Our vision is to become a leading pharmaceutical company within the U.S., offering a growing portfolio of products that improve patients' lives.
At Medicure, we are focused on improving the health of patients by offering a growing portfolio of products and services and ensuring all patients get access to care they need.
At Medicure, our mission is to serve patients by delivering safe and efficacious life-changing medicines
Medicure's Phase 3 clinical trial aims to evaluate the use of its investigational product MC-1 for treatment of a rare pediatric disease called pyridox(am)ine 5'-phosphate oxidase (PNPO) deficiency.
Medicure Inc.– via Marley Drug, creates a direct-to-consumer e-commerce pharmacy solution. The service is available in all 50 states and can fulfill a formulary of over 100 prescription medications.
At Medicure, we are focused on improving the heart health of patients by delivering safe and efficacious cardiovascular medicines and ensuring all patients get access to therapy.
Medicure Announces Early Completion of Enrollment for iSPASM, a Phase 1/2a Exploratory Clinical Trial in Patients with Aneurysmal Subarachnoid Hemorrhage
Leadership
Board of Directors
Our History
Mission and Values
Medicure Marks Its 25th Anniversary
People and Culture
Careers
AGGRASTAT® (tirofiban HCl) injection
Zypitamag®
Pipeline
Drug Safety
Medical Information
Patient Information
Events
Presentations / Conference Calls
Stock Information
Annual Reports
Quarterly Reports
Corporate Governance
Investor Contacts